Advancell secured an oversubscribed $315 million Series D round to accelerate its radiopharma buildout, funding late-stage clinical development and expanding isotope supply and manufacturing infrastructure. The financing is designed to support progression of Advancell’s lead radioligand candidate ADVC-001, a lead-212 PSMA-targeted therapy for metastatic castration-resistant prostate cancer. The capital inflection highlights a continued shift toward fully integrated radiopharmaceutical models that manage both drug development and critical isotope throughput. For developers, manufacturing constraints and supply security have become central determinants of clinical execution. The raise further underscores that isotope-backed strategies are attracting large late-stage investors as the radiopharma pipeline advances beyond early proof-of-concept.